You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Fig. 3

LY3300054 enhances T cell activation in vitro. Panel a: Jurkat-NFAT reporter assay: Each data point represents the average of two technical replicates, with error bars representing the SD. Data are representative of three independent experiments. Panel b: Mixed leukocyte reactions. Supernatants were measured for IFN-γ production by ELISA. Each data point represents the average of 8 replicates, with error bars representing the SEM. Data are representative of multiple experiments and donor T cells/DC pairs. Panel c: Tetanus toxoid recall assay: Supernatants were measured for IFN-γ production by ELISA. Each data point represents the average of 4 replicates, with error bars representing the SD. Data are representative of two experiments with PBMC obtained from different donors. Panels d and e: Gene expression analysis of cell lysate (E) and cytokine level analysis of cell culture supernatant (F) from the mixed leukocyte reactions using QuantiGene Plex and microbead-based immunoassay panels, respectively. Volcano plots show Log2 fold change of gene expression (E) or cytokine levels (F) in the LY3300054 treated group compared to control group. The highlighted circles correspond to differentially expressed genes (DEG) or cytokines that display fold change > 1.7 (black solid vertical line) and p value < 0.05 (horizontal dotted line). Circle sizes are proportional to the level of expression in LY3300054 group. One-way ANOVA was used for statistical analysis. Human IgG1 LY3300054

Back to article page